Prognostic Parameters of Palbociclib in HR+/HER2-Advanced Breast Cancer: A Narrative Review

被引：0

作者：

Wang, Wei ^{[1
,2
]}

Wu, Jiayi ^{[1
,3
]}

Chen, Keyu ^{[1
,3
]}

Wang, Xiaojia ^{[1
,4
]}

Shao, Xiying ^{[1
,4
]}

机构：

[1] Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Med Oncol Breast Canc, Hangzhou, Peoples R China

[2] Wenzhou Med Univ, Dept Clin Med, Wenzhou, Peoples R China

[3] Zhejiang Chinese Med Univ, Dept Clin Med, Hangzhou, Peoples R China

[4] Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Med Oncol Breast Canc, 1,Banshandong Rd, Hangzhou, Peoples R China

来源：

TECHNOLOGY IN CANCER RESEARCH & TREATMENT | 2023年 / 22卷

关键词：

breast cancer; palbociclib; CDK4/6; inhibitor; prognostic parameters;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Recent studies have demonstrated that the combination of Cyclin-Dependent Kinase 4/6 Inhibitor (CDK4/6i) and endocrine therapy (ET) is more effective than ET alone and significantly improves progression-free survival (PFS) and overall survival (OS) in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor-2 negative (HER2-) breast cancer (BC). Palbociclib is the first CDK4/6i approved for use, and its clinical advantages have been shown. However, 30% of patients will continue to develop secondary drug resistance. Therefore, exploring the parameters that can predict the efficacy of Palbociclib and developing a clinical prediction model is essential for evaluating the prognosis of patients.

引用

页数：9

共 50 条

[1] Prognostic Parameters of Palbociclib in HR+/HER2-Advanced Breast Cancer: A Narrative Review
Wang, Wei
Wu, Jiayi
Chen, Keyu
Wang, Xiaojia
Shao, Xiying
TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2023, 22
[2] Patterns and outcomes in HR+/HER2-advanced/metastatic breast cancer patients in Brazil receiving palbociclib
Simon, Patricia
Jain, Ankita
Guarin, Alexandra
Piton, Luciana
Carvalho, Carla Fabrine
Lima, Julia
Nazareth, Felipe
FUTURE ONCOLOGY, 2024,
[3] A systematic literature review of prognostic factors in patients with HR+/HER2-advanced breast cancer in Japan
Hattori, Masaya
Novick, Diego
Takaura, Kana
Tanizawa, Yoshinori
Kawaguchi, Tsutomu
Haro, Josep Maria
Monistrol-Mula, Anna
Onishi, Akira
Iwata, Hiroji
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (10) : 1498 - 1508
[4] Prognostic factors associated with clinical outcomes in HR+, HER2-advanced breast cancer: Systematic literature review
Carter, Gebra C.
Stenger, Keri
Mohanty, Maitreyee
Chong, Amy L.
Basa, Pradeep
Singuru, Shivaprasad
Singh, Sheena
Tongbram, Vanita
Kummel, Sherko
Guarneri, Valentina
Tolaney, Sara M.
CANCER RESEARCH, 2020, 80 (04)
[5] BUDGET IMPACT ANALYSIS OF PALBOCICLIB FOR THE TREATMENT OF PATIENTS WITH HR+/HER2-ADVANCED/METASTATIC BREAST CANCER IN BULGARIA
Djambazov, S.
Slavchev, G.
Velchev, M.
Vekov, T.
VALUE IN HEALTH, 2018, 21 : S22 - S22
[6] Real-World Palbociclib Use in HR+/HER2-Advanced Breast Cancer in Canada: The IRIS Study
Mycock, Katie
Zhan, Lin
Taylor-Stokes, Gavin
Milligan, Gary
Mitra, Debanjali
CURRENT ONCOLOGY, 2021, 28 (01) : 678 - 688
[7] Ribociclib in HR+/HER2-Advanced or Metastatic Breast Cancer Patients
Rascon, Kaitlin
Flajc, Goran
De Angelis, Carmine
Liu, Xinli
Trivedi, Meghana V.
Ekinci, Ekim
ANNALS OF PHARMACOTHERAPY, 2019, 53 (05) : 501 - 509
[8] Matching-adjusted indirect treatment comparison of ribociclib and palbociclib in HR+, HER2-advanced breast cancer
Tremblay, Gabriel
Chandiwana, David
Dolph, Mike
Hearnden, Jaclyn
Forsythe, Anna
Monaco, Mauricio
CANCER MANAGEMENT AND RESEARCH, 2018, 10 : 1319 - 1327
[9] COST-EFFECTIVENESS OF PALBOCICLIB PLUS LETROZOLE IN THE TREATMENT OF HR+/HER2-ADVANCED OR METASTATIC BREAST CANCER IN ECUADOR
Cabezas, M.
Freire, V
Salcedo, E.
Albert, A.
VALUE IN HEALTH, 2018, 21 : S32 - S32
[10] Therapy of HR+/HER2-advanced or metastatic Breast Cancer Palbociclib: Importance of Data from Everyday Care for Therapy
Ruedesheim, Sabine M.
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (05)

← 1 2 3 4 5 →